- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MEDICENNA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Mi | Medicenna Therapeutics Corp: Medicenna highlights MDNA11 melanoma trial data | 3 | Stockwatch | ||
| Mi | Stocks in Play: Medicenna Therapeutics Corp. | 1 | Baystreet.ca | ||
| 29.05. | Medicenna Therapeutics Corp: Medicenna Therapeutics closes $4.44M public offering | 1 | Stockwatch | ||
| 28.05. | Medicenna Therapeutics Corp.: Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs | 1 | GlobeNewswire (USA) | ||
| 22.05. | Medicenna Therapeutics Corp: Medicenna files prospectus for $5-million offering | 1 | Stockwatch | ||
| 22.05. | Medicenna Therapeutics Corp.: Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet | 3 | GlobeNewswire (USA) | ||
| 19.05. | Medicenna Therapeutics Corp: Medicenna sets out terms of public offering | 1 | Stockwatch | ||
| 19.05. | Stocks in Play: Medicenna Therapeutics Corp. | 1 | Baystreet.ca | ||
| 19.05. | Medicenna prices public offering at $0.50 per unit | 5 | Investing.com | ||
| 13.05. | Medicenna launches public offering to fund clinical programs | 2 | Investing.com | ||
| 13.05. | Medicenna launches marketed public offering of securities | 1 | Seeking Alpha | ||
| 13.05. | Medicenna Therapeutics Corp.: Medicenna Announces the Launch of a Marketed Public Offering of Securities | 1 | GlobeNewswire (USA) | ||
| 12.05. | Stocks in Play: Medicenna Therapeutics Corp. | 2 | Baystreet.ca | ||
| 12.05. | Medicenna Therapeutics Corp.: Medicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma | 166 | GlobeNewswire (Europe) | NEO-CYT marks the first evaluation of MDNA11 in earlier-stage cancers, as a potentially curative treatment; extends development beyond the heavily pretreated metastatic setting of the ongoing Phase... ► Artikel lesen | |
| 21.04. | Medicenna Therapeutics Corp: Medicenna releases MDNA113 preclinical data | 1 | Stockwatch | ||
| 21.04. | Medicenna Therapeutics Corp.: Medicenna Presents Positive Data Demonstrating Superior Safety and Efficacy Potential of its First-in-Class anti-PD-1 x IL-2 Bifunctional Superkine MDNA113 at AACR 2026 | 1 | GlobeNewswire (USA) | ||
| 14.04. | Stocks in Play: Medicenna Therapeutics Corp. | 1 | Baystreet.ca | ||
| 09.04. | Medicenna Therapeutics Corp: Medicenna appoints Ibrahim as chief medical officer | 3 | Stockwatch | ||
| 18.03. | Medicenna Therapeutics Corp.: Medicenna to Present Preclinical Data from its First-in-Class Tumor Anchored and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the AACR Annual Meeting 2026 | 1 | GlobeNewswire (USA) | ||
| 13.02. | Medicenna Therapeutics Corp: Medicenna's Dec. 31 cash at $10.6 million | 1 | Stockwatch |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TANGO THERAPEUTICS | 30,940 | +0,03 % | Tango Therapeutics stock soars on promising pancreatic cancer data | ||
| NURIX THERAPEUTICS | 15,640 | 0,00 % | Biotech-Partnerschaft: Roche greift zu: Dieser Milliarden-Deal lässt Anleger aufhorchen | © Foto: Vladimir Borovic - Adobe StockRoche steigt mit einem milliardenschweren Deal bei Nurix ein. Im Fokus steht ein vielversprechender Wirkstoff gegen Krebs, Autoimmun- und Nervenkrankheiten.Der... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,110 | 0,00 % | All You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to Buy | ||
| COGENT BIOSCIENCES | 31,160 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) ... | Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 82,94 | -0,08 % | RBC Capital raises Apogee Therapeutics stock price target to $97 | ||
| PRAXIS PRECISION MEDICINES | 253,12 | -0,05 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| ERASCA | 12,870 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| BEAM THERAPEUTICS | 29,780 | 0,00 % | Beam Therapeutics Inc. - 8-K, Current Report | ||
| AMYLYX PHARMACEUTICALS | 13,010 | 0,00 % | H.C. Wainwright reiterates Amylyx stock rating on PBH trial insights | ||
| KINIKSA PHARMACEUTICALS | 49,040 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST- (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $930 - $945 million -- KPL-387... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 22,500 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing | - Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront and up to $100 million once certain commercial milestones are met - - $500 million committed... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 17,000 | 0,00 % | Pictet closes $1.53bn Monte Rosa Co-Investments VI fund, exceeding target | ||
| DYNE THERAPEUTICS | 16,820 | +0,06 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1) | - Registrational expansion cohort enrolled 71 participants; topline data planned for Q1 2027 - WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage... ► Artikel lesen | |
| CG ONCOLOGY | 54,36 | -0,07 % | CG Oncology, Inc. - 8-K, Current Report | ||
| RELAY THERAPEUTICS | 13,660 | 0,00 % | Relay Therapeutics Shares Jump 18% |
MEDICENNA THERAPEUTICS CORP gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEDICENNA THERAPEUTICS CORP finden Sie auf Wallstreet Online.